Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
Identifieur interne : 001252 ( Istex/Corpus ); précédent : 001251; suivant : 001253Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
Auteurs : Estelle Dellapina ; Angélique Gerdelat-Mas ; Fabienne Ory-Magne ; Laure Pourcel ; Monique Galitzky ; Fabienne Calvas ; Marion Simonetta-Moreau ; Claire Thalamas ; Pierre Payoux ; Christine Brefel-CourbonSource :
- Movement Disorders [ 0885-3185 ] ; 2011-01.
English descriptors
Abstract
Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain‐induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H 215O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved. © 2010 Movement Disorder Society.
Url:
DOI: 10.1002/mds.23406
Links to Exploration step
ISTEX:0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study</title><author><name sortKey="Dellapina, Estelle" sort="Dellapina, Estelle" uniqKey="Dellapina E" first="Estelle" last="Dellapina">Estelle Dellapina</name><affiliation><mods:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Gerdelat As, Angelique" sort="Gerdelat As, Angelique" uniqKey="Gerdelat As A" first="Angélique" last="Gerdelat-Mas">Angélique Gerdelat-Mas</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Ory Agne, Fabienne" sort="Ory Agne, Fabienne" uniqKey="Ory Agne F" first="Fabienne" last="Ory-Magne">Fabienne Ory-Magne</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Pourcel, Laure" sort="Pourcel, Laure" uniqKey="Pourcel L" first="Laure" last="Pourcel">Laure Pourcel</name><affiliation><mods:affiliation>Unité de Pharmacoépidémiologie, Faculté de médecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name><affiliation><mods:affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Calvas, Fabienne" sort="Calvas, Fabienne" uniqKey="Calvas F" first="Fabienne" last="Calvas">Fabienne Calvas</name><affiliation><mods:affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Simonetta Oreau, Marion" sort="Simonetta Oreau, Marion" uniqKey="Simonetta Oreau M" first="Marion" last="Simonetta-Moreau">Marion Simonetta-Moreau</name><affiliation><mods:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name><affiliation><mods:affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><affiliation><mods:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Faculté de médecine, Toulouse, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23406</idno><idno type="url">https://api.istex.fr/document/0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001252</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study</title><author><name sortKey="Dellapina, Estelle" sort="Dellapina, Estelle" uniqKey="Dellapina E" first="Estelle" last="Dellapina">Estelle Dellapina</name><affiliation><mods:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Gerdelat As, Angelique" sort="Gerdelat As, Angelique" uniqKey="Gerdelat As A" first="Angélique" last="Gerdelat-Mas">Angélique Gerdelat-Mas</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Ory Agne, Fabienne" sort="Ory Agne, Fabienne" uniqKey="Ory Agne F" first="Fabienne" last="Ory-Magne">Fabienne Ory-Magne</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Pourcel, Laure" sort="Pourcel, Laure" uniqKey="Pourcel L" first="Laure" last="Pourcel">Laure Pourcel</name><affiliation><mods:affiliation>Unité de Pharmacoépidémiologie, Faculté de médecine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name><affiliation><mods:affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Calvas, Fabienne" sort="Calvas, Fabienne" uniqKey="Calvas F" first="Fabienne" last="Calvas">Fabienne Calvas</name><affiliation><mods:affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Simonetta Oreau, Marion" sort="Simonetta Oreau, Marion" uniqKey="Simonetta Oreau M" first="Marion" last="Simonetta-Moreau">Marion Simonetta-Moreau</name><affiliation><mods:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name><affiliation><mods:affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><affiliation><mods:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Faculté de médecine, Toulouse, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-01">2011-01</date><biblScope unit="vol">26</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="153">153</biblScope><biblScope unit="page" to="157">157</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891</idno><idno type="DOI">10.1002/mds.23406</idno><idno type="ArticleID">MDS23406</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>H 215O positron emission tomography</term><term>Parkinson's disease</term><term>apomorphine</term><term>pain threshold</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain‐induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H 215O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved. © 2010 Movement Disorder Society.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Estelle Dellapina MSc</name><affiliations><json:string>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</json:string><json:string>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</json:string></affiliations></json:item><json:item><name>Angélique Gerdelat‐Mas MD</name><affiliations><json:string>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</json:string></affiliations></json:item><json:item><name>Fabienne Ory‐Magne MD</name><affiliations><json:string>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</json:string></affiliations></json:item><json:item><name>Laure Pourcel MSc</name><affiliations><json:string>Unité de Pharmacoépidémiologie, Faculté de médecine, Toulouse, France</json:string></affiliations></json:item><json:item><name>Monique Galitzky MD</name><affiliations><json:string>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</json:string></affiliations></json:item><json:item><name>Fabienne Calvas MD</name><affiliations><json:string>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</json:string></affiliations></json:item><json:item><name>Marion Simonetta‐Moreau MD, PhD</name><affiliations><json:string>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</json:string><json:string>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</json:string><json:string>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</json:string></affiliations></json:item><json:item><name>Claire Thalamas MD</name><affiliations><json:string>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</json:string></affiliations></json:item><json:item><name>Pierre Payoux MD, PhD</name><affiliations><json:string>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</json:string><json:string>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</json:string></affiliations></json:item><json:item><name>Christine Brefel‐Courbon MD</name><affiliations><json:string>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</json:string><json:string>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</json:string><json:string>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</json:string><json:string>Service de Pharmacologie Clinique, Faculté de médecine, Toulouse, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pain threshold</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>H 215O positron emission tomography</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>apomorphine</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain‐induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H 215O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved. © 2010 Movement Disorder Society.</abstract><qualityIndicators><score>6.416</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>844</abstractCharCount><pdfWordCount>25607</pdfWordCount><pdfCharCount>171968</pdfCharCount><pdfPageCount>44</pdfPageCount><abstractWordCount>118</abstractWordCount></qualityIndicators><title>Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study</title><genre><json:string>Serial article</json:string></genre><host><volume>26</volume><pages><total>5</total><last>157</last><first>153</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23406</json:string></doi><id>0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study</title><author><persName><forename type="first">Estelle</forename><surname>Dellapina</surname><roleName type="degree">MSc</roleName></persName><note type="correspondence"><p>Correspondence: Inserm U825, Pavillon Riser, CHU Purpan, 31059 Toulouse, France</p></note><affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation></author><author><persName><forename type="first">Angélique</forename><surname>Gerdelat‐Mas</surname><roleName type="degree">MD</roleName></persName><affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</affiliation></author><author><persName><forename type="first">Fabienne</forename><surname>Ory‐Magne</surname><roleName type="degree">MD</roleName></persName><affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</affiliation></author><author><persName><forename type="first">Laure</forename><surname>Pourcel</surname><roleName type="degree">MSc</roleName></persName><affiliation>Unité de Pharmacoépidémiologie, Faculté de médecine, Toulouse, France</affiliation></author><author><persName><forename type="first">Monique</forename><surname>Galitzky</surname><roleName type="degree">MD</roleName></persName><affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</affiliation></author><author><persName><forename type="first">Fabienne</forename><surname>Calvas</surname><roleName type="degree">MD</roleName></persName><affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</affiliation></author><author><persName><forename type="first">Marion</forename><surname>Simonetta‐Moreau</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</affiliation></author><author><persName><forename type="first">Claire</forename><surname>Thalamas</surname><roleName type="degree">MD</roleName></persName><affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</affiliation></author><author><persName><forename type="first">Pierre</forename><surname>Payoux</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Brefel‐Courbon</surname><roleName type="degree">MD</roleName></persName><affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</affiliation><affiliation>Service de Pharmacologie Clinique, Faculté de médecine, Toulouse, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-01"></date><biblScope unit="vol">26</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="153">153</biblScope><biblScope unit="page" to="157">157</biblScope></imprint></monogr><idno type="istex">0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891</idno><idno type="DOI">10.1002/mds.23406</idno><idno type="ArticleID">MDS23406</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain‐induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H 215O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved. © 2010 Movement Disorder Society.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>pain threshold</term></item><item><term>H 215O positron emission tomography</term></item><item><term>apomorphine</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-06-09">Received</change><change when="2010-07-25">Registration</change><change when="2011-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v26.1</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2011-01">January 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="280" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23406</doi><idGroup><id type="unit" value="MDS23406"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-06-09"></event><event type="manuscriptRevised" date="2010-07-22"></event><event type="manuscriptAccepted" date="2010-07-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.6 mode:FullText mathml2tex" date="2012-07-17"></event><event type="publishedOnlineEarlyUnpaginated" date="2010-10-19"></event><event type="publishedOnlineFinalForm" date="2011-02-14"></event><event type="firstOnline" date="2010-10-19"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">153</numbering><numbering type="pageLast">157</numbering></numberingGroup><correspondenceTo>Inserm U825, Pavillon Riser, CHU Purpan, 31059 Toulouse, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23406.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="23"></count><count type="wordTotal" number="4084"></count></countGroup><titleGroup><title type="main" xml:lang="en">Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study<link href="#fn3"></link></title><title type="short" xml:lang="en">Apomorphine Effect on Pain in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Estelle</givenNames><familyName>Dellapina</familyName><degrees>MSc</degrees></personName><contactDetails><email>estelle.dellapina@inserm.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Angélique</givenNames><familyName>Gerdelat‐Mas</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Fabienne</givenNames><familyName>Ory‐Magne</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Laure</givenNames><familyName>Pourcel</familyName><degrees>MSc</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Monique</givenNames><familyName>Galitzky</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Fabienne</givenNames><familyName>Calvas</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1 #af2 #af3"><personName><givenNames>Marion</givenNames><familyName>Simonetta‐Moreau</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Claire</givenNames><familyName>Thalamas</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Pierre</givenNames><familyName>Payoux</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1 #af2 #af3 #af6"><personName><givenNames>Christine</givenNames><familyName>Brefel‐Courbon</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Unité de Pharmacoépidémiologie, Faculté de médecine, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="FR" type="organization"><unparsedAffiliation>Service de Pharmacologie Clinique, Faculté de médecine, Toulouse, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">pain threshold</keyword><keyword xml:id="kwd3">H<math altimg="urn:x-wiley:08853185:media:MDS23406:tex2gif-stack-2" wiley:location="equation/tex2gif-stack-2.gif"><msubsup><mtext> </mtext><mrow><mtext>2</mtext></mrow><mrow><mtext>15</mtext></mrow></msubsup></math>O positron emission tomography</keyword><keyword xml:id="kwd4">apomorphine</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain‐induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H<math altimg="urn:x-wiley:08853185:media:MDS23406:tex2gif-stack-1" wiley:location="equation/tex2gif-stack-1.gif"><msubsup><mtext> </mtext><mrow><mtext>2</mtext></mrow><mrow><mtext>15</mtext></mrow></msubsup></math>O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved. © 2010 Movement Disorder Society.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn3"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Apomorphine Effect on Pain in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study</title></titleInfo><name type="personal"><namePart type="given">Estelle</namePart><namePart type="family">Dellapina</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><description>Correspondence: Inserm U825, Pavillon Riser, CHU Purpan, 31059 Toulouse, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Angélique</namePart><namePart type="family">Gerdelat‐Mas</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabienne</namePart><namePart type="family">Ory‐Magne</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laure</namePart><namePart type="family">Pourcel</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Unité de Pharmacoépidémiologie, Faculté de médecine, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Monique</namePart><namePart type="family">Galitzky</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabienne</namePart><namePart type="family">Calvas</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marion</namePart><namePart type="family">Simonetta‐Moreau</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claire</namePart><namePart type="family">Thalamas</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Inserm, Centre d'Investigation Clinique, CHU Purpan, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Payoux</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Brefel‐Courbon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, Toulouse, France</affiliation><affiliation>Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France</affiliation><affiliation>Service de Pharmacologie Clinique, Faculté de médecine, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-01</dateIssued><dateCaptured encoding="w3cdtf">2010-06-09</dateCaptured><dateValid encoding="w3cdtf">2010-07-25</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">23</extent><extent unit="words">4084</extent></physicalDescription><abstract lang="en">Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain‐induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H 215O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved. © 2010 Movement Disorder Society.</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>pain threshold</topic><topic>H 215O positron emission tomography</topic><topic>apomorphine</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>153</start><end>157</end><total>5</total></extent></part></relatedItem><identifier type="istex">0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891</identifier><identifier type="DOI">10.1002/mds.23406</identifier><identifier type="ArticleID">MDS23406</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001252 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001252 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0FE03C86D5A2B78BBBBBF3C8873095BA4F7F1891
|texte= Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
}}
| This area was generated with Dilib version V0.6.23. |  |